<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00767351</url>
  </required_header>
  <id_info>
    <org_study_id>001</org_study_id>
    <nct_id>NCT00767351</nct_id>
  </id_info>
  <brief_title>Variation in Serum Levels of Metformin in Patients With Reduced Renal Function</brief_title>
  <official_title>Intraindividual Variation of Serum Metformin in a Cohort of Patients With Type 2 DM and Moderately Reduced Renal Function</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Skane University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Skane University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Metformin is widely used for treatment of type 2 diabetes mellitus. Side-effects are few and&#xD;
      mainly from the gastrointestinal tract. Since metformin is cleared from the blood exclusively&#xD;
      via the kidneys reduced renal function is a relative contraindication. We have earlier&#xD;
      demonstrated that metformin safely can be used to a lower GFR level of 30 ml/min/1.73. Below&#xD;
      that level the risk of lactacidosis, a severe complication, increases.&#xD;
&#xD;
      In the present study we plan to analyse serum levels of metformin repeatedly in patients with&#xD;
      moderate renal failure (CKD = GFR of 30-60 ml/min/1.73). Blood samples will be taken as&#xD;
      trough values in the morning, week 0, 2, 4, and 8 and at four weeks a blood sample will be&#xD;
      taken two hours after intake of the morning dose of metformin. Renal function will be&#xD;
      estimated with creatinine and cystatin C at each occasion. The intraindividual variation of&#xD;
      metformin will be calculated.&#xD;
&#xD;
      The study rests on a new method for measuring metformin. The technique uses Liquid&#xD;
      Chromatography Tandem Mass Spectometry (LCMSMS). Proteins are removed from serum by adding&#xD;
      acetonitrile to the sample. After centrifugation a diluted portion of the supernatant is&#xD;
      injected into the LCMSMS-system. The total runtime for a sample is 6 minutes.&#xD;
&#xD;
      The study will show if variation in serum levels of metformin measured in the same patient is&#xD;
      high or low and thus give us better understanding whether a change i serum level is due to&#xD;
      biological variation or to increased retention caused by progressive renal failure.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2008</start_date>
  <completion_date type="Actual">July 2009</completion_date>
  <primary_completion_date type="Actual">June 2009</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <enrollment type="Actual">30</enrollment>
  <condition>Diabetes Mellitus Type 2</condition>
  <condition>Metformin</condition>
  <condition>Pharmacokinetics</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with type 2 DM followed at the out-patient department at the hospital will be&#xD;
        asked to join the study&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients above the age of 18 years with type 2 diabetes mellitus.&#xD;
&#xD;
          -  Reduced renal function measured as estimated GFR (below 60 ml/min/1.73).&#xD;
&#xD;
          -  Treatment with metformin on going.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Severely reduced GFR (&lt; 30 ml(min/1.73)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <removed_countries>
    <country>Sweden</country>
  </removed_countries>
  <verification_date>September 2018</verification_date>
  <study_first_submitted>October 6, 2008</study_first_submitted>
  <study_first_submitted_qc>October 6, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 7, 2008</study_first_posted>
  <last_update_submitted>September 6, 2018</last_update_submitted>
  <last_update_submitted_qc>September 6, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">September 10, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Skane University Hospital</investigator_affiliation>
    <investigator_full_name>Gunnar Sterner</investigator_full_name>
    <investigator_title>PhD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

